Literature DB >> 18440602

Surgery for high-grade gliomas in a developing country: survival estimation using a simple stratification system.

José Lorenzoni1, Alejandro Torrico, Pablo Villanueva, Alessandra Gederlini, Gonzalo Torrealba.   

Abstract

BACKGROUND: In spite of great technological advances in diagnostic and therapeutic tools, survival in patients with HGG has not changed significantly in the last years. Judicious management in each case needs survival estimation after surgery. We used a simple stratification system evaluating the histology, patient's age, and the KPS.
METHODS: We retrospectively made an analysis of survival in 103 patients with HGG operated in a 10-year period (1990--1999). Three significant prognostic variables were studied: histology, patient's age, and KPS. The BS-MG was calculated, adding the partial score (0 or 1) obtained for each variable. This score ranges from 0 (worse condition) to 3 (best condition).
RESULTS: Overall, MS was 12 months. For glioblastoma multiforme, AA, and ODS, it was 10, 20, and 19 months, respectively (P = .0001). Patients 44 years old or younger had an MS of 28 months, higher than 10 months for patients older than 45 years (P < .0001). Median survival was 20 months for patients with KPS 80 or higher, and 9 months for those with KPS 70 or lower (P = .02). It was 3.5 months in patients with BS-MG = 0, 9 months for BS-MG = 1, 22 months for BS-MG = 2, and 55 months for BS-MG = 3 (P < .0001.).
CONCLUSIONS: Survival presented here is comparable with those previously reported despite lacking the most sophisticated surgical technique. The stratification score that includes the 3 most important variables for survival seems to be simple and reliable for survival estimation.

Entities:  

Mesh:

Year:  2008        PMID: 18440602     DOI: 10.1016/j.surneu.2007.08.004

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  5 in total

1.  Initial care and outcome of glioblastoma multiforme patients in 2 diverse health care scenarios in Brazil: does public versus private health care matter?.

Authors:  Luiz Victor Maia Loureiro; Lucíola de Barros Pontes; Donato Callegaro-Filho; Ludmila de Oliveira Koch; Eduardo Weltman; Elivane da Silva Victor; Adrialdo José Santos; Lia Raquel Rodrigues Borges; Roberto Araújo Segreto; Suzana Maria Fleury Malheiros
Journal:  Neuro Oncol       Date:  2014-07       Impact factor: 12.300

2.  Post-surgical therapeutic approaches to glioblastoma patients submitted to biopsy (BA) or "partial" resection (PR): the possibilities to treat also them without renunciations. Study from the Brescia Neuro-Oncology Group.

Authors:  Michela Buglione; Paolo Borghetti; Sara Pedretti; Luca Triggiani; Marco Maria Fontanella; Giannantonio Spena; Salvatore Grisanti; Roberto Liserre; Luigi Pietro Poliani; Stefano Gipponi; Luigi Spiazzi; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2015-03-15       Impact factor: 3.469

3.  Outcome of patients with primary glioblastoma in Chile: single centre series.

Authors:  Mariana Sinning; Michael Frelinghuysen; Marcela Gallegos; Andrés Cordova; Patricio Paredes; Conrado Vogel; Emi Sujima; Carlos Kamiya-Matsuoka; Felipe Valdivia
Journal:  Ecancermedicalscience       Date:  2021-02-10

4.  Changing the clinical course of glioma patients by preoperative motor mapping with navigated transcranial magnetic brain stimulation.

Authors:  Sandro M Krieg; Nico Sollmann; Thomas Obermueller; Jamil Sabih; Lucia Bulubas; Chiara Negwer; Tobias Moser; Doris Droese; Tobias Boeckh-Behrens; Florian Ringel; Bernhard Meyer
Journal:  BMC Cancer       Date:  2015-04-08       Impact factor: 4.430

5.  Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities.

Authors:  Arlhee Diaz-Miqueli; Giselle Saurez Martinez
Journal:  Onco Targets Ther       Date:  2013-07-24       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.